667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer

D.S Hong, R-H Xu + Show 10 more

https://doi.org/10.1016/j.annonc.2023.09.1853

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2023
Citations: 1

Affiliation: The University of Texas MD Anderson Cancer Center, Sun Yat-sen University Cancer Center, Cancer Trials Ireland, Peking University Cancer Hospital, Institute Curie, National Cancer Center Hospital East, Bayer (Canada), Bayer (Switzerland), Children's Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center

#First-line Treatment For Patients #Tropomyosin Receptor Kinase + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer

Full Text

Published version (

Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title

Journal

Date

Author

View more papers

Translate this paper in your preferred language
Listen to the abstract of this paper

Save
Share
Export